MAIA Biotechnology, Inc. MAIA 深 沪
等待开盘 02-07 09:30:00 美东时间
1.97
+0.060
+3.14%
华盛通- 最 高2.0499
- 今 开1.96
- 成交量 54.45万股
- 最 低 1.94
- 昨 收 1.91
- 总市值 7295.36万
- 52周最高 3.19
- 市盈率 静 --
- 换手率 1.47%
- 52周最低 0.87
- 委 比 -70.94%
- 总股本 3703.23万
- 历史最高 9.64
- 量 比 0.78
- 振 幅 5.75%
- 历史最低 0.82
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nuwellis (NASDAQ:NUWE) shares rose 81.5% to $3.9 during Tuesday's regu...
01-28 01:05
MAIA Biotechnology Announces Milestones And Growth Catalysts For 2026; Initial Measures Of Efficacy From Phase 3 Study, Conclusion Of Part C Of Phase 2 Study, Engage In Regulatory Interactions With The FDA, Clinical Development Of Second-generation Molecules To Start In Phase 1 Trials
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update on 2025 achievements
01-20 23:25
MAIA Biotechnology announces $1.51M private placement
MAIA Biotechnology (NYSE:MAIA) announced on Tuesday that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.23M shares of common stock at a price of $1.224 per s...
2025-12-17 05:33
MAIA Biotechnology Doses First Patient In Phase 3 Trial Of Ategenosine Plus Checkpoint Inhibitor For Advanced NSCLC
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapyCHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- MAIA
2025-12-11 22:10
MAIA Biotechnology Makes Open-Market Purchases: CEO Buys 94,300 Shares At An Average Price Of $1.08/Share; Board Members Acquire 88,145 Shares At An Average Price Of $1.04/Share, Totaling 182,445 Shares Combined
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the
2025-12-01 22:20
MAIA Biotechnology Highlights Phase 2 THIO‑101 Expansion And Phase 3 THIO‑104 Trials Of Telomere Targeting Agent Ateganosine For NSCLC At SITC 2025; FDA Grants Fast Track Designation
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countriesPosters for Phase 2 and Phase 3 clinical trials availableCHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA
2025-11-21 22:05
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology announced the enrollment of five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 clinical trial, which evaluates ateganosine in combination with immune checkpoint inhibitors for advanced NSCLC patients resistant to prior therapies. The trial is ongoing across multiple continents, allowing access to a larger patient population. Dr. Saadettin Kiliçkap highlighted the potential of ateganosine to addr...
2025-10-27 14:45
MAIA Biotechnology Showcases Promising Cancer Trial Results
MAIA Biotechnology, Inc. ( ($MAIA) ) just unveiled an announcement. On October ...
2025-10-23 21:47
MAIA Biotechnology Reports Efficacy Of Ateganosine In High-Risk Non-Small Cell Lung Cancer At ESMO 2025
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage
2025-10-23 20:38
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. recently highlighted at the ESMO Congress 2025 in Berlin the exceptional results of its Phase 2 and Phase 3 clinical trials of ateganosine in non-small cell lung cancer (NSCLC). The company reported a third-line NSCLC patient showing 30-month survival, an outstanding measure for high-risk cancers with limited treatment options. Ateganosine, a telomere-targeting agent, has demonst...
2025-10-23 12:36
